Introduction
============

Coronary artery disease (CAD) is a frequent cardiovascular disease that is mainly caused by coronary atherosclerosis. It may result in arterial blood vessel stenosis, blockage or spasm, further leading to myocardial ischemia and hypoxia and/or a series of lesions ([@b1-etm-0-0-9064]). CAD may also cause further conditions, including angina pectoris, arrhythmia, heart failure or sudden death ([@b4-etm-0-0-9064],[@b5-etm-0-0-9064]). Therefore, early diagnosis and treatment of CAD are of high clinical significance. In recent years, as medicine, science and technologies continue to progress and imaging technologies develop rapidly, the spatial and temporal resolution of CT scanning, which is widely used in the clinical diagnosis of CAD, have been markedly improved ([@b6-etm-0-0-9064]).

Adipose tissue, which is now considered as an endocrine organ, secretes various fat factors to affect the metabolism and certain pathological processes, including inflammation, oxidative stress and apoptosis ([@b9-etm-0-0-9064],[@b10-etm-0-0-9064]). Among adipocytokines, visfatin may be involved in the development of obesity-associated diseases, including diabetes and cardiovascular disease. Adiponectin is considered as an important anti-atherogenic and anti-diabetic protein and also as an anti-inflammatory protein ([@b9-etm-0-0-9064]). In recent years, the association between epicardial adipose tissue (EAT) and atherosclerosis has attracted increasing attention ([@b11-etm-0-0-9064],[@b12-etm-0-0-9064]). EAT is a specialized energy storage organ located between the myocardium and epicardium, which serve to provide energy ([@b13-etm-0-0-9064]). Previous studies have reported that EAT potentially causes local inflammation and may be seen as a marker for the risk of cardiovascular disease ([@b16-etm-0-0-9064]). Studies have indicated that EAT is an important risk factor for atherosclerotic diseases and metabolic syndrome ([@b17-etm-0-0-9064],[@b18-etm-0-0-9064]). The correlation between EAT and CAD has been previously reported; however, it is controversial whether EAT may be regarded as a marker to predict the occurrence and development of CAD ([@b19-etm-0-0-9064]). Therefore, in the present study, the epicardial fat volume (EFV) was measured by CT scanning to explore the correlation between the EFV and coronary artery lesions and left ventricular function, so as to provide a theoretical basis for the diagnosis of clinical CAD.

Patients and methods
====================

### Patient population

The present study was approved by the Medical Ethics Committee of The Affiliated Changzhou No. 2 People\'s Hospital of Nanjing Medical University (Changzhou, China) and all patients volunteered to participate in the present study and provided written informed consent. A total of 61 patients with known or suspected CAD who received cardiac CT scanning and coronary angiography at Changzhou No. 2 People\'s Hospital, the Affiliated Hospital of Nanjing Medical University (Changzhou, China) between December 2017 and October 2018 were enrolled. The inclusion criterion was as follows: One or more major coronary arteries with a diameter stenosis of ≥50%. Patients with iodine contrast agent allergy, arrhythmias and hepatic and/or renal insufficiency were excluded. Those subjects who previously had a coronary artery operation or coronary bypass surgery, or those with respiratory diseases who cannot hold their breath for \>10 sec were also excluded. The treatment of these patients mainly included administration of anti-hypertension drugs (amlodipine tablets, furosemide tables, spironolactone), statin drugs (pravastatin tablets, atorvastatin calcium tablets, rosuvastatin calcium tablets), anti-platelet agglutination drugs (aspirin enteric-coated tablet, clopidogrel hydrogen sulphate tablets) and nitrates (nitroglycerin tablet).

### Data collection

Prior to CT scanning, the age, gender, family history of CAD, history of myocardial infarction, as well as smoking and drinking status of all participants were recorded. The body height and weight of the participants were measured to calculate the body mass index (BMI) and body surface area (BSA) as follows: BMI (kg/m^2^) = body weight (kg)/height (m)^2^, BSA (m^2^) = 0.006 x height (cm) + 0.013 x body weight (kg)-0.153. A catheter-tipped micromanometer (SPC-454D, Millar Instrument Co.) and a polygraph system (RMC-2000; Nihon Kohden, Inc.), were used to measure and record the pulse pressure, systolic blood pressure (SBP) and diastolic blood pressure (DBP). Hypertension was defined as SBP ≥140 mmHg and/or DBP ≥90 mmHg or use of anti-hypertensive drugs. An automatic biochemistry analyzer (7060; Hitachi) was used to determine the levels of low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), total cholesterol (TC) and fasting blood glucose (FBG). Dyslipidemia was defined as TC \>200 mg/dl, LDL-C ≥130 mg/dl and HDL-C \<40 mg/dl for males or HDL-C \<50 mg/dl for females or those who used lipid-lowering medications. Diabetes mellitus was defined as FBG ≥126 mg/dl or treatment with hypoglycemic drugs.

### Instruments and scanning methods

The CT examination equipment used in the present study was a 64-slice spiral CT scanner (SOMATOM Definition; Siemens AG) and the scanning parameters were as follows: Tube voltage, 120 kV; tube current, 90-160 mA; thread pitch, 0.2; slice thickness, 0.60-1.25 mm; reconstruction thickness and reconstruction interval, 5 mm. As the contrast media, Ultravist (370 mg I/ml; Schering AG) and Omnipaque (350 mgI/ml; GE Healthcare Ltd) at a volume of 60-80 ml (scaled to body weight) was injected at 4.5-5.0 ml/sec. After the injection, 40 ml normal saline was injected at the same flow rate.

### Measurement of EFV

After the scanning, the EFV data were analyzed using the Volume Viewer program (version 1.2.0.0) of the semi-automatic off-line workstation (Simens AG). The measurements were performed by two experienced radiologists who were blinded regarding the clinical condition of the patients (presence or absence of CAD). The pericardium was manually traced from the bifurcation of the pulmonary trunk to the last section containing any images of the heart to obtain a region of interest (ROI). The Hounsfield units (HU) threshold of -190 to -30 HU was used to isolate the fat content inside the ROI. The threshold value was visually adjusted by the radiologists to ensure that all adipose tissue in the pericardium was included ([Fig. 1](#f1-etm-0-0-9064){ref-type="fig"}).

### Assessment of the severity of CAD

Coronary angiography was performed on the patients by 64-slice multislice spiral CT. The degree of coronary artery stenosis was evaluated according to the coronary artery image evaluation criteria of the American Heart Association ([@b22-etm-0-0-9064]). The severity of CAD was based on the evaluation criteria of the Gensini scoring system ([@b23-etm-0-0-9064]) and analyzed by two experienced radiologists; a consensus was reached through discussion in the event of any disagreement. The degree of coronary artery stenosis was divided into groups of 25, 50, 75, 90, 99 and 100%, with corresponding scores of 1, 2, 4, 8, 16 and 32, respectively. The coronary arteries in different segments were multiplied by the corresponding coefficients as follows: Score x5 for left major disease; score x2.5 for left anterior descending (LAD) proximal segment; score x1.5 for LAD middle segment; score x1 for LAD distal segment; score x1 for first diagonal branch; score x0.5 for second diagonal branch; score x2.5 for left circumflex artery (LCX) proximal segment, score x1 for LCX distal segment and posterior descending branch; score x0.5 for posterior lateral artery; score x1 for right coronary artery proximal, middle and distal segment and posterior descending branch. The final total integral was the sum of the integral of lesion branch, with a higher score indicating a more serious lesion degree.

### Detection of left ventricular function

The participants underwent a complete transthoracic echocardiographic examination using the GE Vingmed System V (GE Healthcare) with a 3.5-MHz phased-array probe. Three consecutive cycles were averaged for each parameter and analyzed by two cardiologists blinded to the data of the participants. Left ventricular end diastolic diameter (LVEDD), interventricular septal thickness (IVS), left ventricular posterior wall thickness (LVPW), left ventricular mass (LVM) and LVM index (LVMI) were measured and recorded according to the recommendations of the American Society of Echocardiography ([@b24-etm-0-0-9064]).

### Statistical analysis

The statistical analysis was performed using SPSS version 20.0 (IBM Corp.). Kolmogorov-Smirnov test was used to assess normality of data distribution. The enumeration data were expressed as n (%) and non-normally distributed data were expressed as the median and the 25 and 75th percentile quartiles (Q1 and Q3). The degrees of correlation between variables were determined by performing a Pearson\'s correlation analysis. Kruskal-Wallis analysis of variance was used to compare differences among the groups. P*-*values were 2-sided and a value of P\<0.05 was considered to indicate statistical significance.

Results
=======

### Clinical characteristics of the participants

The clinical characteristics of the participants are provided in [Table I](#tI-etm-0-0-9064){ref-type="table"}. A total of 61 patients with suspected CAD, including 29 (52.5%) females and 32 (47.5%) males, with a median age of 63 years (Q1 and Q3: 55 and 73 years), were selected as the research subjects in this study. The patients had a median BMI of 23.37 kg/m^2^ (Q1 and Q3: 21.8 and 26.3 kg/m^2^), a median BSA of 1.65 m^2^ (Q1 and Q3: 1.6 and 1.8 m^2^), a median pulse of 75 beats/min (Q1 and Q3: 69 and 88 beats/min), a median SBP of 130 mmHg (Q1 and Q3: 120 and 146 mmHg) and a median DBP of 76 mmHg (Q1 and Q3: 70 and 88 mmHg). Among the 61 participants, 28 (45.9%) had hypertension, 13 (21.3%) had diabetes mellitus, 7 (11.5%) had dyslipidemia and 2 (3.3%) had a history of myocardial infarction. Regarding the smoking and drinking status of the participants, 11 (18.0%) were current smokers and 6 (9.8%) were former smokers, while 44 (72.1%) had never smoked; furthermore, 5 (8.2%) were drinkers and 56 (91.8%) were non-drinkers. One participant (1.6%) had a family history of CAD and the remaining 60 participants (98.4%) did not have a family history of CAD. Among the 61 subjects, 43 patients (70.5%) received medications and 18 (29.5%) did not take any medications.

### Association between EFV and risk factors for CAD

The distribution of EFV among the participants is provided in [Fig. 2A](#f2-etm-0-0-9064){ref-type="fig"} and [Table II](#tII-etm-0-0-9064){ref-type="table"}; the median EFV among all participants was 86.41 cm^3^ (Q1 and Q3: 66.66 and 112.23 cm^3^). The median Gensini score among all participants was 4 (Q1 and Q3: 0 and 9). [Table II](#tII-etm-0-0-9064){ref-type="table"} provides the median EFV for subgroups based on the risk factors associated with CAD. In addition, the association between EFV and risk factors associated with CAD was evaluated, and it was revealed that hypertension, diabetes mellitus, dyslipidemia, history of myocardial infarction and smoking had no significant effect on the EFV (P\>0.05).

### Correlation analysis

As provided in [Fig. 2B-E](#f2-etm-0-0-9064){ref-type="fig"}, the Pearson\'s correlation analysis indicated that the EFV was significantly positively correlated with the BMI (r=0.479, P\<0.0001), IVS (r=0.436, P=0.004), LVPW (r=0.350, P=0.0058), LVEDD (r=0.265, P=0.0388), LVM (r=0.445, P=0.0003) and LVMI (r=0.371, P=0.0035). However, there was no significant correlation between the EFV and the Gensini score (r=0.131, P=0.31375).

Discussion
==========

CAD is a common disease seriously affecting human health and the risk factors include smoking, drinking, obesity, hypertension, dyslipidemia, diabetes mellitus, family history of CAD, history of myocardial infarction and/or abdominal fat accumulation ([@b25-etm-0-0-9064]). In addition to these factors, EAT has been reported to be involved in the pathogenesis of CAD ([@b28-etm-0-0-9064]). As an endocrine organ, EAT may directly affect the vascular wall and promote the progression of atherosclerosis by releasing inflammatory cytokines and mediators ([@b29-etm-0-0-9064],[@b30-etm-0-0-9064]). At present, the volume of epicardial fat may be determined by a variety of imaging techniques, including echocardiography, CT and cardiovascular magnetic resonance ([@b31-etm-0-0-9064],[@b32-etm-0-0-9064]). Due to its non-invasiveness, reliable results and capacity to provide abundant information, CT imaging technology is widely used in the detection of CAD and EAT ([@b33-etm-0-0-9064],[@b34-etm-0-0-9064]).

In the present study, CT scanning and standard methods were used to evaluate the degree of coronary artery lesions. It should be noted that in the present study, the association between EFV and clinical outcomes was not assessed, though it was attempted to analyze the association between the EFV and the severity of CAD. To date, the association between EAT and the severity of CAD has been under debate ([@b35-etm-0-0-9064]). In most studies, the EFV was proved to be significantly correlated with the Gensini score, suggesting that the EFV is closely associated with CAD ([@b36-etm-0-0-9064],[@b37-etm-0-0-9064]). Conversely, no correlation between the EFV and Gensini score was detected in the present study, which may be explained by the fact that only one patient in the study had a Gensini score of \>60 (lack of critical patients). On the other hand, in the study by Tanami *et al* ([@b38-etm-0-0-9064]), a cohort of 320 patients with suspected CAD who underwent 320-detector row CT angiography exhibited a lack of association between the EFV and the presence and severity of CAD, which was similar to the present results. In addition, there are also certain differences between the present study and that of Tanami *et al* ([@b38-etm-0-0-9064]): In the present study, the correlation between the EFV and Gensini score was determined, while the latter study explored the correlation between EFV and the coronary calcification score.

It has been reported that the EFV was elevated with the increase of risk factors for CAD and was significantly associated with hypertension, diabetes, age and hyperlipidemia ([@b39-etm-0-0-9064]). Hell *et al* ([@b40-etm-0-0-9064]) determined the volume and density of EAT in CAD patients by using non-contrast CT, indicating that hypertension was the only risk factor affecting the volume and density of EAT. However, it has also been revealed that EAT is independent of traditional risk factors and contributes to fatal and non-fatal coronary events regardless of cardiovascular risk factors ([@b41-etm-0-0-9064],[@b42-etm-0-0-9064]). Hachiya *et al* ([@b43-etm-0-0-9064]) analyzed 134 patients who underwent multi-detector CT to assess them for CAD and observed that the increase in EFV was associated with augmented central aortic pressure and left ventricular diastolic dysfunction, but not with age, gender, hypertension, dyslipidemia, diabetes mellitus or prior myocardial infarction. In the present study, the risk factors for CAD, including hypertension, diabetes mellitus, dyslipidemia, history of myocardial infarction and smoking had no effect on the EFV. These conflicting results may be due to limitations of the measurement methods.

Overweight and obesity are important risk factors for CAD and the relevant evaluation indexes include BMI, waist circumference, hip circumference and percentage of body/visceral fat ([@b44-etm-0-0-9064]). EAT is a type of visceral fat with metabolic activity and is a source of multiple fat factors ([@b47-etm-0-0-9064]). Previous studies have indicated a direct association of EAT with the BMI and waist circumference ([@b48-etm-0-0-9064],[@b49-etm-0-0-9064]). In the present study, the EFV was positively correlated with the BMI, suggesting that with the increase of the EFV, the BMI and the risk of CAD were also increased. In addition, EFV was positively correlated with IVS, LVPW, LVEDD, LVM and LVMI. In the analysis of the association between EVF and left cardiac function, the indicators of left cardiac function adopted in the present study were different from those used in other studies ([@b50-etm-0-0-9064],[@b51-etm-0-0-9064]). Left ventricular dysfunction significantly increases the rate of mortality in CAD patients ([@b52-etm-0-0-9064]). Multiple studies have confirmed the correlation between EAT and LVM, left atrial size and left ventricular diastolic dysfunction ([@b53-etm-0-0-9064]), and this may be explained by the fact that the secretion of pro-inflammatory cytokines, free fatty acids and atherogenic cytokines by EAT may lead to arteriosclerosis ([@b56-etm-0-0-9064]). Vural *et al* ([@b57-etm-0-0-9064]) reported that patients with left ventricular diastolic dysfunction had a significantly increased EFV. Nerlekar *et al* ([@b58-etm-0-0-9064]) indicated that an increased EFV was associated with diastolic dysfunction. In addition, EAT is directly associated with the myocardium, may be subjected to local compressive forces and may affect the morphology and function of the heart by paracrine and mechanical interactions ([@b57-etm-0-0-9064],[@b59-etm-0-0-9064]). EAT induces inflammation by secreting a variety of adipokines and inflammatory factors, and persistent inflammation may lead to collagen deposition, thereby causing impaired left ventricular relaxation function and finally affecting the diastolic function of the left ventricle ([@b58-etm-0-0-9064]). Previous studies have reported that epicardial fat may increase the accumulation of myocardial triglycerides, which may cause apoptosis of myocardial cells, increase oxidative stress and damage of cardiac function ([@b60-etm-0-0-9064],[@b61-etm-0-0-9064]). In a state of cardiovascular disease, the EAT dilates, becoming hypoxic and dysfunctional and recruiting phagocytic cells, which may lead to increasing detrimental adipocytokines and eventually impaired cardiac function ([@b61-etm-0-0-9064]). In view of this, the EFV is correlated with the BMI and left ventricular function, which has certain clinical significance for the early diagnosis of diseases linked to obesity and left ventricular function.

The present study has certain limitations. For instance, the number of patients included in the study was small and patients with severe coronary artery lesions were not included in the study, as only 1 out of the 61 patients with suspected CAD had a Gensini score of \>60. In the present study, the EFV was associated with left heart function, whereas poor left heart function is not a direct diagnostic basis for CAD, as coronary angiography remains the diagnostic gold standard for CAD ([@b62-etm-0-0-9064]). In addition, a previous study has indicated that abdominal adipose tissue was an important index for cardiovascular disease ([@b63-etm-0-0-9064]). Detection of abdominal adipose tissue may be more effective in fat evaluation and this will be our future research direction.

In conclusion, in the present study, the EFV determined using CT scanning was not associated with CAD based on the Gensini scores, but was positively correlated with the BMI, IVS, LVPW, LVEDD, LVM and LVMI. The association between EFV and BMI and left ventricular function still has certain clinical guiding significance. Further studies are required to determine the association between the EFV and coronary heart disease, and it may be suggested that the cohort size should be expanded or the evaluation indicators (e.g. the elasticity of ascending aorta) may be increased to enhance the reliability. In addition, the guiding significance of the EFV should be verified by examining the association between the EFV and heart diseases other than CAD. The association between the EFV and left ventricular diastolic function should be further explored and whether the location of epicardial fat affects left ventricular function also remains to be investigated.
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![Measurement of EFV on CT. (A) Coronary image for determination of epicardial fat range. (B) Sagittal image for determination of epicardial fat range. (C) Cross-section image for determination of epicardial fat range. (D) The EFV of this subject with CAD was 137.50 cm^3^. A total of 61 patients with suspected CAD received cardiac CT scanning (64-slice spiral CT scanner; SOMATOM Definition; Siemens AG) and the EFV data were then analyzed using a Volume Viewer program of a semi-automatic off-line workstation (Simens AG). The range of fat density was -190 to -30 HU. The yellow area indicates the total volume of epicardial fat tissue distributed around the heart and arrows indicate the epicardial fat tissue. VOl, volume; L Eval Limit, lower evaluation limit; U Eval Limit, upper evaluation limit; HU, Hounsfield units; EFV, epicardial fat volume; CAD, coronary artery disease.](etm-20-04-2961-g00){#f1-etm-0-0-9064}

![Association between EFV and left ventricular function analyzed by Pearson correlation analysis. (A) Violin plot indicating the distribution of EFV among the study participants; the median EFV was 86.84 cm^3^ (Q1 and Q3, 66.66 and 112.23 cm^3^, respectively). (B) Correlation between EFV and BMI (r=0.479, P\<0.0001). (C) Correlation between EFV and Gensini score (r=0.131, P=0.3137). (D) Correlation between EFV and IVS (r=0.436, P=0.004), LVPW (r=0.350, P=0.0058) and LVEDD (r=0.265, P=0.0388). (E) Correlation between EFV and LVM (r=0.445, P=0.0003) and LVMI (r=0.371, P=0.0035). EFV, epicardial fat volume; BMI, body mass index; IVS, interventricular septal thickness; LVPW, left ventricular posterior wall thickness; LVEDD, left ventricular end diastolic diameter; LVM, left ventricular mass; LVMI, LVM index; Q1, first quartile; Q3, third quartile.](etm-20-04-2961-g01){#f2-etm-0-0-9064}

###### 

Basic data of the included subjects (n=61).

  Characteristic                          Value
  --------------------------------------- --------------------
  Age (years)                             63 (55, 73)
  Sex                                     
       Male                               32 (52.5)
       Female                             29 (47.5)
  BMI (kg/m^2^)                           23.37 (21.8, 26.3)
  BSA (m^2^)                              1.65 (1.6,1.8)
  Pulse (beats/min)                       75 (69, 88)
  SBP (mmHg)                              130 (120,146)
  DBP (mmHg)                              76 (70, 88)
  Coronary risk factor                    
       Hypertension                       28 (45.9)
       Diabetes mellitus                  13 (21.3)
       Dyslipidemia                       7 (11.5)
       History of myocardial infarction   2 (3.3)
  Smoking status                          
       Current smoker                     11 (18.0)
       Former smoker                      6 (9.8)
       Never smoker                       44 (72.1)
  Drinking status                         
       Yes                                5 (8.2)
       No                                 56 (91.8)
  Family history of CAD                   
       Yes                                1 (1.6)
       No                                 60 (98.4)
  Intake of medications                   
       Yes                                43 (70.5)
       No                                 18 (29.5)

Values are expressed as median (Q1, Q3) or n (%). BMI, body mass index; BSA, body surface area; SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary artery disease; Q1, first quartile; Q3, third quartile.

###### 

Association between EFV and risk factors of CAD.

  Item/subgroup                      n    EFV                      P-value
  ---------------------------------- ---- ------------------------ ---------
  All patients                       61   86.41 (66.66, 112.23)     
  Hypertension                                                     0.57
       Yes                           28   80.68 (70.92, 114.67)     
       No                            33   90.12 (58.69, 109.67)     
  Diabetes mellitus                                                0.42
       Yes                           13   89.06 (68.69, 127.41)     
       No                            48   85.52 (66.34, 106.28)     
  Dyslipidemia                                                     0.96
       Yes                           7    76.73 (71.23,89.06)       
       No                            54   86.61 (65.68, 113.00)     
  History of myocardial infarction                                 0.08
       Yes                           2    60.15                     
       No                            59   86.81 (67.20, 112.88)     
  Smoking                                                          0.79
       Current smoker                11   71.41 (66.22, 112.88)     
       Former smoker                 6    104.37 (57.85, 122.54)    
       Never smoker                  44   86.61 (66.83,105.74)      

Values are expressed as the median (Q1, Q3). P-values were calculated using Kruskal-Wallis analysis of variance; P-values were 2-sided and P\<0.05 was considered to indicate statistical significance. Q1, first quartile; Q3, third quartile; CAD, coronary artery disease; EFV epicardial fat volume.
